Anixa Biosciences Inc. has announced the completion of enrollment in its Phase 1 clinical trial for a novel breast cancer vaccine, developed in partnership with Cleveland Clinic. The trial, which includes 35 women across three distinct patient cohorts, is fully funded by a grant from the U.S. Department of Defense. The vaccine aims to stimulate the immune system to target breast cancer before it can recur or develop. Encouraged by preliminary results showing a high level of immune response, Anixa is planning for Phase 2 trials and will submit trial data for presentation at a major scientific meeting.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.